Drugmaker seeks approval for RSV vaccine for 50-59 year olds

ViewDrugmaker GSK said its RSV, or respiratory syncytial virus, vaccine Arexvy is safe and effective for adults ages 50-59 who have a higher risk of complications from RSV. GSK submitted findings from its Phase 3 trial to the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on...